ArticleJournal of cardiovascular electrophysiology2025
Ivabradine Use in Premature Infants With Accelerated Idioventricular Rhythm.
Article in Journal of cardiovascular electrophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionIvabradine has been recently introduced to treat focal atrial tachycardia and junctional ectopic tachycardia in children. Its use for treating ventricular tachyarrhythmias, specifically accelerated idioventricular rhythm (AIVR), remains limited. METHODS AND
resultsWe report two cases of premature infants with AIVR successfully treated with ivabradine as monotherapy after other antiarrhythmic agents had failed. The first infant had a structurally normal heart and the second infant a truncus arteriosus. In both patients, sinus rhythm was restored with ivabradine. Side effects only consisted of brief, hemodynamically insignificant episodes of bradycardia.
conclusionsIvabradine represents a promising antiarrhythmic agent for treating AIVR in preterm infants. Its ability to maintain hemodynamic stability in this age group makes ivabradine an attractive option for managing AIVR, especially in the postoperative setting. Further research is warranted to explore the safety, dosage, and mechanistic action of ivabradine for AIVR in the premature, neonatal infant patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.